CTIS2022-502869-17-01招募中1 期
FusionVAC22_01
niversitaetsklinikum Tuebingen0 个研究点目标入组 20 人开始时间: 2023年6月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusiotumor entities carrying the oncogenic driver fusion DNAJB1-PRKACA, fibrolamellar hepatocellular carcinomaCTIS2022-502869-17-00niversitaetsklinikum Tuebingen20
招募中
1 期
A Phase I study to evaluate the safety and dosimetry of 68Ga-labelled OncoFAP derivatives in patients with solid tumorsPatients with breast cancer, colorectal cancer, oesophageal cancer and pancreatic adenocarcinoma.MedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2CTIS2022-500902-16-00Philogen S.p.A.20
进行中（未招募）
1 期
A study to investigate VMX-C001 in healthy volunteers.To restore coagulation in patients taking DOACs who are experiencing bleeding or who require reversal of anticoagulation prior to urgent surgery.MedDRA version: 20.0Level: PTClassification code: 10009773Term: Coagulation factor X level Class: 100000004848CTIS2024-514339-87-00VarmX B.V.12
招募中
1 期
Study of safety, tolerability and efficacy of DFV890 in participants with myeloid diseasesCTIS2022-501406-36-00ovartis Pharma AG80
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced MalignanciesAdvanced MalignanciesMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2024-514010-12-00Invox Pharma Limited131